La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
62 hedge funds and large institutions have $78.6M invested in La Jolla Pharmaceutical Company in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 31 reducing their positions, and 23 closing their positions.
13% more call options, than puts
Call options by funds: $304K | Put options by funds: $268K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less capital invested
Capital invested by funds: $88.1M → $78.6M (-$9.52M)
18% less funds holding
Funds holding: 76 → 62 (-14)
61% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 23
65% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.76M |
| 2 |
Millennium Management
New York
|
+$968K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$880K |
| 4 |
E
Ergoteles
New York
|
+$353K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$311K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.77M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.56M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.29M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.1M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$772K |
LJPC Hedge Fund Activity: Q2 2021 in Review
62 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2021, worth a combined $78.6M — down 11% from $88.1M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LJPC and 9 opened new positions — a net loss of 14 holders — while 31 trimmed existing stakes and 11 added.
The largest buyer was Tang Capital Management, adding an estimated $2.76M. The largest seller was BlackRock, cutting an estimated $4.77M.
- 62 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2021, down from 76 in Q1 2021.
- Funds reported $78.6M of La Jolla Pharmaceutical Company stock for Q2 2021, down 11% quarter-over-quarter.
- 9 funds opened new La Jolla Pharmaceutical Company positions in Q2 2021 and 23 closed out, a net change of -14 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q2 2021 was Tang Capital Management, an estimated $2.76M added.
- The largest La Jolla Pharmaceutical Company seller in Q2 2021 was BlackRock, an estimated $4.77M sold.
Based on aggregated 13F filings for Q2 2021.